Biodexa Pharmaceuticals Announces Phase 2 Trial Results Of eRapa In Familial Adenomatous Polyposis; 75% Non-Progression Rate At 12 Months, 17% Median Decrease In Polyp Burden; Cohort 2 Shows 81% Non-Progression And 29% Median Decrease Informing Phase 3 Dosage; Results Presented At 2024 InSIGHT Meeting
Portfolio Pulse from Benzinga Newsdesk
Biodexa Pharmaceuticals announced positive Phase 2 trial results for eRapa in treating Familial Adenomatous Polyposis, showing significant non-progression and reduction in polyp burden. These results will inform Phase 3 dosage. The findings were presented at the 2024 InSIGHT meeting.
June 24, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biodexa Pharmaceuticals announced positive Phase 2 trial results for eRapa, showing significant non-progression and reduction in polyp burden in patients with Familial Adenomatous Polyposis. These results will inform Phase 3 dosage.
The positive Phase 2 trial results for eRapa indicate significant efficacy in treating Familial Adenomatous Polyposis, which is likely to boost investor confidence and positively impact BDRX's stock price in the short term. The announcement at the 2024 InSIGHT meeting adds credibility and visibility to the findings.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100